JP2018533601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533601A5 JP2018533601A5 JP2018524369A JP2018524369A JP2018533601A5 JP 2018533601 A5 JP2018533601 A5 JP 2018533601A5 JP 2018524369 A JP2018524369 A JP 2018524369A JP 2018524369 A JP2018524369 A JP 2018524369A JP 2018533601 A5 JP2018533601 A5 JP 2018533601A5
- Authority
- JP
- Japan
- Prior art keywords
- oral pharmaceutical
- pharmaceutical formulation
- formulation according
- oral
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 23
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 6
- LRSYFEZBIMVWRY-VWMHFEHESA-N (2s)-2,5-diaminopentanoic acid;2-phenylacetic acid Chemical compound NCCC[C@H](N)C(O)=O.OC(=O)CC1=CC=CC=C1 LRSYFEZBIMVWRY-VWMHFEHESA-N 0.000 claims 5
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 3
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 229940049953 phenylacetate Drugs 0.000 claims 2
- 229960003424 phenylacetic acid Drugs 0.000 claims 2
- 239000003279 phenylacetic acid Substances 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010020575 Hyperammonaemia Diseases 0.000 claims 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009969 flowable effect Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000030954 urea cycle disease Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021213640A JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | Ｌ－オルニチンフェニルアセテート製剤 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255300P | 2015-11-13 | 2015-11-13 | |
| US62/255,300 | 2015-11-13 | ||
| US201662276754P | 2016-01-08 | 2016-01-08 | |
| US62/276,754 | 2016-01-08 | ||
| US15/133,087 US20160338982A1 (en) | 2015-04-20 | 2016-04-19 | Formulations of l-ornithine phenylacetate |
| US15/133,087 | 2016-04-19 | ||
| PCT/US2016/061678 WO2017083758A1 (en) | 2015-11-13 | 2016-11-11 | Formulation of l-ornithine phenylacetate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021213640A Division JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | Ｌ－オルニチンフェニルアセテート製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533601A JP2018533601A (ja) | 2018-11-15 |
| JP2018533601A5 true JP2018533601A5 (enExample) | 2019-12-19 |
| JP7294807B2 JP7294807B2 (ja) | 2023-06-20 |
Family
ID=58695607
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524369A Active JP7294807B2 (ja) | 2015-11-13 | 2016-11-11 | Ｌ－オルニチンフェニルアセテート製剤 |
| JP2021213640A Pending JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | Ｌ－オルニチンフェニルアセテート製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021213640A Pending JP2022058446A (ja) | 2015-11-13 | 2021-12-28 | Ｌ－オルニチンフェニルアセテート製剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3373923A4 (enExample) |
| JP (2) | JP7294807B2 (enExample) |
| KR (2) | KR20180086431A (enExample) |
| CN (2) | CN108366983A (enExample) |
| AU (2) | AU2016353350B2 (enExample) |
| BR (1) | BR112018009349A8 (enExample) |
| CA (1) | CA3004331A1 (enExample) |
| IL (1) | IL258630B2 (enExample) |
| MX (2) | MX389926B (enExample) |
| RU (1) | RU2018113801A (enExample) |
| SG (1) | SG11201802987UA (enExample) |
| WO (1) | WO2017083758A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| MX2020001765A (es) | 2017-08-14 | 2020-07-29 | Axcella Health Inc | Composiciones de aminoacidos para el tratamiento de enfermedad hepatica. |
| CN112839643A (zh) | 2018-06-20 | 2021-05-25 | 胺细拉健康公司 | 用于治疗肌肉中脂肪浸润的组合物及方法 |
| PH12022550738A1 (en) * | 2019-10-16 | 2023-05-08 | Mallinckrodt Entpr Llc | Dosages and uses of ornithine phenylacetate for treating hyperammonemia |
| WO2024261477A1 (en) | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| GB0426141D0 (en) * | 2004-11-26 | 2004-12-29 | Ucl Biomedica Plc | Treatment |
| SI2153870T1 (sl) * | 2004-11-26 | 2014-05-30 | Ucl Business Plc | Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije |
| DE102007009243A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets |
| HUE035921T2 (en) * | 2009-04-03 | 2018-05-28 | Ocera Therapeutics Inc | L-ornithine phenyl acetate and methods of making thereof |
| AU2015221466B2 (en) * | 2009-04-03 | 2017-02-02 | Ocera Therapeutics, Inc. | L-ornithine phenyl acetate and methods of making thereof |
| AU2014250643B2 (en) * | 2009-06-08 | 2016-07-14 | Ocera Therapeutics, Inc. | Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate |
| CN104434894A (zh) * | 2009-06-08 | 2015-03-25 | Ucl商业有限公司 | 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能 |
| US8946473B2 (en) * | 2010-10-06 | 2015-02-03 | Ocera Therapeutics, Inc. | Methods of making L-ornithine phenyl acetate |
| CN102993037B (zh) * | 2012-11-20 | 2015-03-04 | 南京工业大学 | 一种l-鸟氨酸苯乙酸盐的制备方法 |
| CN103705490B (zh) * | 2013-10-31 | 2016-08-17 | 蚌埠丰原医药科技发展有限公司 | 一种门冬氨酸鸟氨酸的缓释制剂及其制备工艺 |
| ES2769000T3 (es) * | 2014-11-24 | 2020-06-24 | Ucl Business Ltd | Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco |
| CN107708684A (zh) * | 2015-04-20 | 2018-02-16 | 欧塞拉治疗有限公司 | L‑鸟氨酸苯乙酸盐制剂 |
| WO2017031131A1 (en) * | 2015-08-18 | 2017-02-23 | Ocera Therapeutics, Inc. | Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate |
| HK1257679A1 (zh) * | 2015-09-25 | 2019-10-25 | Ocera Therapeutics, Inc. | 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失 |
-
2016
- 2016-11-11 CN CN201680066488.5A patent/CN108366983A/zh active Pending
- 2016-11-11 SG SG11201802987UA patent/SG11201802987UA/en unknown
- 2016-11-11 KR KR1020187016373A patent/KR20180086431A/ko not_active Ceased
- 2016-11-11 CA CA3004331A patent/CA3004331A1/en not_active Abandoned
- 2016-11-11 BR BR112018009349A patent/BR112018009349A8/pt not_active Application Discontinuation
- 2016-11-11 JP JP2018524369A patent/JP7294807B2/ja active Active
- 2016-11-11 WO PCT/US2016/061678 patent/WO2017083758A1/en not_active Ceased
- 2016-11-11 RU RU2018113801A patent/RU2018113801A/ru not_active Application Discontinuation
- 2016-11-11 CN CN202111062923.6A patent/CN113768863A/zh active Pending
- 2016-11-11 AU AU2016353350A patent/AU2016353350B2/en not_active Ceased
- 2016-11-11 MX MX2018005088A patent/MX389926B/es unknown
- 2016-11-11 EP EP16865158.6A patent/EP3373923A4/en not_active Withdrawn
- 2016-11-11 KR KR1020247042587A patent/KR20250023993A/ko active Pending
-
2018
- 2018-04-11 IL IL258630A patent/IL258630B2/en unknown
- 2018-04-25 MX MX2022001517A patent/MX2022001517A/es unknown
-
2021
- 2021-12-21 AU AU2021290236A patent/AU2021290236A1/en not_active Abandoned
- 2021-12-28 JP JP2021213640A patent/JP2022058446A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513171A5 (enExample) | ||
| JP2018533601A5 (enExample) | ||
| JP2015503593A5 (enExample) | ||
| RU2017137643A (ru) | Составы l-орнитин фенилацетата | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| HRP20192133T1 (hr) | Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze | |
| RU2016124765A (ru) | ПРИМЕНЕНИЕ ГИНЗЕНОЗИДА Rg3 В ПРИГОТОВЛЕНИИ ЛЕКАРСТВЕННОГО ПРЕПАРАТА ДЛЯ ПРОФИЛАКТИКИ И/ИЛИ ЛЕЧЕНИЯ ДЕМЕНЦИИ, И ЛЕКАРСТВЕННЫЙ ПРЕПАРАТ ДЛЯ ЛЕЧЕНИЯ ДЕМЕНЦИИ | |
| JP2014111603A5 (enExample) | ||
| JP2013505205A5 (enExample) | ||
| CA2709997A1 (en) | Pirfenidone treatment for patients with atypical liver function | |
| JP2008520736A5 (enExample) | ||
| JP2012193216A5 (enExample) | ||
| JP2013512919A5 (enExample) | ||
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| BR122023026625A2 (pt) | Uso do ácido 15-hidroxieicosapentaenoico ou derivados farmaceuticamente aceitáveis do mesmo | |
| RU2018113801A (ru) | Составы l-орнитин фенилацетата | |
| JP2015531749A5 (enExample) | ||
| RU2018146504A (ru) | Лечение внутрипеченочных холестатических заболеваний | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2016512247A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| JP2015120758A5 (enExample) | ||
| JP2014510780A5 (enExample) | ||
| HK1252411A1 (zh) | 磷脂酰肌醇3-激酶抑制剂的给药方案 |